

# Natasha Arulappan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8358046/publications.pdf>

Version: 2024-02-01

6  
papers

627  
citations

1684188

5  
h-index

1872680

6  
g-index

6  
all docs

6  
docs citations

6  
times ranked

923  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. <i>New England Journal of Medicine</i> , 2019, 381, 803-815.	27.0	447
2	Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. <i>Lancet HIV</i> , 2020, 7, e666-e676.	4.7	145
3	Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial. <i>Lancet HIV</i> , 2019, 6, e428-e437.	4.7	14
4	Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 80, 224-233.	2.1	11
5	CD4 cell count variability with repeat testing in South Africa: Should reporting include both absolute counts and ranges of plausible values?. <i>International Journal of STD and AIDS</i> , 2018, 29, 1048-1056.	1.1	6
6	Is laboratory screening prior to antiretroviral treatment useful in Johannesburg, South Africa? Baseline findings of a clinical trial. <i>BMC Public Health</i> , 2017, 17, 445.	2.9	4